Once-weekly insulin icodec: pharmacokinetic and pharmacodynamic properties in type 1 diabetes

被引：0
|
作者：
Hoevelmann, U. [1 ]
Engberg, S. [2 ]
Heise, T. [1 ]
Kristensen, N. R. [2 ]
Norgreen, L. [3 ]
Ribel-Madsen, R. [2 ]
Zijlstra, E. [1 ]
Haahr, H. [2 ]
机构：
[1] Profil, Neuss, Germany
[2] Novo Nordisk, Soborg, Denmark
[3] Novo Nordisk, Aalborg, Denmark
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
779
引用
收藏
页码：S399 / S400
页数：2
相关论文
共 50 条
  • [21] Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus
    Westergaard, Lisbet
    Alifrangis, Lene
    Buckley, Stephen T.
    Coester, Hans Veit
    Klitgaard, Thomas
    Kristensen, Niels R.
    Nishimura, Erica
    Norgreen, Lea
    Rocha, Thais M. P.
    Steensgaard, Dorte B.
    Vegge, Andreas
    Plum-Morschel, Leona
    CLINICAL DRUG INVESTIGATION, 2024, 44 (11) : 849 - 861
  • [22] Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes by ethnicity and race: ONWARDS 1-5
    Lingvay, I.
    Bangsgaard, K. O.
    Desouza, C.
    Fragao-Marques, M.
    Navarria, A.
    Vianna, A.
    DIABETOLOGIA, 2024, 67 : S375 - S376
  • [23] Impact of Age on the Efficacy and Safety of Once-Weekly Insulin Icodec vs. Once-Daily Insulin in Type 2 Diabetes (ONWARDS 1-5)
    Vianna, Andre G. D.
    Desouza, Cyrus
    Laugesen, Christian
    Marques, Mariana Fragao
    Nielsen, Pernille Hojlund
    Shaikh, Shehla S.
    Lingvay, Ildiko
    DIABETES, 2024, 73
  • [24] Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes
    Heise, Tim
    Chien, Jenny
    Beals, John M.
    Benson, Charles
    Klein, Oliver
    Moyers, Julie S.
    Haupt, Axel
    Pratt, Edward John
    DIABETES OBESITY & METABOLISM, 2023, 25 (04): : 1080 - 1090
  • [25] Pharmacokinetic/Pharmacodynamic Modeling of Efficacy and Hypoglycemia Rate When Switching From Once-Daily Basal Insulin to Once-Weekly Insulin Icodec Without or With a One-Time Additional Dose in Insulin-Experienced Individuals With Type 2 Diabetes
    Lingvay, Ildiko
    Asbjoernsdottir, Boerg
    Kristensen, Niels R.
    Laugesen, Christian
    Vianna, Andre
    Knop, Filip K.
    ENDOCRINE PRACTICE, 2025, 31 (02) : 147 - 151
  • [26] Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in individuals with type 2 diabetes by kidney function: ONWARDS 1-5
    Cheng, A. Y. Y.
    Rossing, P.
    Benamar, M.
    Laugesen, C.
    Nielsen, P. H.
    Bajaj, H. S.
    DIABETOLOGIA, 2024, 67 : S375 - S375
  • [27] No evidence of increased physical activity-related hypoglycaemia with once-weekly insulin icodec vs once-daily basal insulin in type 1 diabetes: ONWARDS 6
    Sourij, H.
    Bracken, R.
    Asong, M.
    Carstensen, L.
    Watt, S. Kehlet
    Philis-Tsimikas, A.
    DIABETOLOGIA, 2024, 67 : S7 - S8
  • [28] Once-weekly insulin icodec and hospitalisation: insights from the ONWARDS 1-6 trials
    Philis-Tsimikas, A.
    Bache, J. K.
    Bari, T. J.
    Salvesen-Sykes, K.
    Kellerer, M.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S401 - S401
  • [29] Economic Evaluation of Once-Weekly Insulin Icodec from Italian NHS Perspective
    Torre, Enrico
    Di Matteo, Sergio
    Bruno, Giacomo Matteo
    Martinotti, Chiara
    Bottaro, Luigi Carlo
    Colombo, Giorgio Lorenzo
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2024, 16 : 799 - 811
  • [30] Hypoglycaemia frequency and physiological response to double or triple doses of once-weekly insulin icodec versus once-daily insulin glargine in type 2 diabetes
    Pieber, T. R.
    Arfelt, K. N.
    Cailleteau, R.
    Thomsen, K. M. Due
    Hart, M.
    Mursic, I.
    Svehlikova, E.
    Urschitz, M.
    Haahr, H.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S333 - S333
12345